

Sector Update


December 27, 2023

Companies covered in the report

Name of the Company	Recommendation
Aarti Industries	ACCUMULATE
Clean Science and Tech.	HOLD
Deepak Nitrite	REDUCE
Fine Organic Industries	HOLD
Gujarat Fluoroc.	REDUCE
Laxmi Organic Ind.	REDUCE
Navin Fluorine Inter.	BUY
NOCIL	REDUCE
SRF	HOLD
Jubilant Ingrevia Ltd	HOLD
Vinati Organics	ACCUMULATE

Most Relevant Charts or Tables from the Update which needs to be highlighted

Interesting Read



Fine Organic Industries (FINEORG IN)
Rating: HOLD | CMP: Rs4,250 | TP: Rs4,252

November 21, 2023

Company Update

■ Change in Estimates | ■ Target | ■ Price

Change in Estimates

	Current	Previous
EPS (Rs.)	10.02	10.02
EPS (Rs.)	25.458	26.731
EPS (Rs.)	6.844	6.844
EPS (Rs.)	138.9	141.7

Key Financials - Standalone

	FY23	FY24E	FY25E	FY26E
Revenue (Rs. m)	28,291	24,246	24,448	24,711
EBITDA (Rs. m)	7,813	5,274	5,544	5,817
Margin (%)	28.2	21.7	22.6	23.6
PAT (Rs. m)	8,908	4,338	4,338	4,344
EPS (Rs.)	102.2	49.9	50.2	50.7
EPS (Rs.)	158.8	68.6	73.2	74.8
EPS (Rs.)	9.3	-	-	-
EPS (Rs.)	6.2	-	-	-
EPS (Rs.)	47.2	25.0	27.9	28.9
EPS (Rs.)	47.2	20.4	24.9	27.9
EPS (Rs.)	4.1	4.2	4.4	4.2
EBITDA (Rs. m)	161	211	213	207
EPS (Rs.)	22.1	25.9	27.1	26.9
PBV (x)	8.4	7.1	6.1	5.4

Key Data

	FINEORG IN	FINEORG IN
52W High / Low	Rs. 1,322 / Rs. 4,231	Rs. 1,322 / Rs. 4,231
Current Price	Rs. 4,250	Rs. 4,252
Market Cap	Rs. 1,200	Rs. 1,200
Shares Outstanding	282,000,000	282,000,000
30 Day Avg. Daily Trade	Rs. 139,544	Rs. 139,544

Shareholding Pattern (%)

	50.00
Foreign	1.78
Domestic	48.22
Public & Others	49.99
Promoter (Share %)	50.00

Stock Performance (%)

	100	50	0
Accum	(10.1)	(4.1)	(28.3)
Hold	(11.2)	(22.2)	(24.4)

Swarnendu Bhushan
swarnendubhushan@plindia.com | 91-22-66322260

Weak demand in eucamide to cloud earnings

Quick Pointers:

- Global lacklustre demand of petrochemical to keep profitability in check.
- No update on land allocation or capacity enhancement.

Fine Organic (FINEORG) reported a phenomenal ~60% YoY upturn growth (average each quarter) from Q4FY23 to Q2FY24, post which revenue growth declined to 16% in Q4FY23 and then registered de-growth of 29%/42% YoY in Q1FY24/Q2FY24. We understand that de-growth is primarily due to weakness in demand of eucamide, the main product of FINEORG and will likely continue for a while. We do not change our estimates due to lack of any capacity additions and lacklustre demand of key products. We expect ROIC at 46-47% over FY24-26. The stock is trading at 14x FY24 EPS and 21x FY24 EV/EBITDA. We reiterate our 'Hold' rating with TP of Rs. 4252 (unchanged) valuing it at 20x FY24 EPS of Rs.441. Any development in land acquisition or any inorganic expansion will be key risks to our call.

Eucamide demand expected to be weak. Eucamide is the largest product of FINEORG which goes into polyethylene (PE) and polypropylene (PP) manufacturing. Our research suggests that due to lacklustre demand of petrochemicals, demand outlook is likely to remain under stress. Eucic acid is derived from rapeseed oil which mixed with ammonia over a catalyst, results in production of Eucamide – a key product of FINEORG. Eucamide is used as an anionic, catalytic agent in PE/PP manufacturing, dispersing agent in ink manufacturing, Production of paper, textile, foam-stabilizer and metal-wire drawing also make use of Eucamide. We believe Eucamide demand to remain weak in near term and should improve post FY24E.

Petrochemical demand remains weak: Due to lack of global demand, cracker capacities have declined to 77.0% in Q1FY24 before recovering marginally to 81.1% in Q2FY24. China is expected to continue capacity additions to remove import dependency for petrochemicals. It has already reduced its import dependency on HDPE from 50% in 2019 to 25% in 2022E. Similarly, in PP, it has reduced its dependency on imports from 27% in 2019 to 11% in 2022E. As a result of continued capacity additions, we believe global rates are expected to remain weak for some time to come.

Demand of Eucamide expected to remain weak: Polymer additives, are indeed required in small quantities. For example, 0.05-0.1% (w/w) stabilizers are required for polymer while slip agents are required 0.1-1% (w/w). Although the quantities appear small, all together including high realizations with respect to base petrochemicals, form a substantial amount and when petroleum margins are under pressure, realizations of Eucamide are expected to be under pressure too, in our view.

Sluggish demand in export market persists: The domestic export mix has reduced from 32.8% in FY23 to 50.5% in Q2FY24, owing to sluggish demand in the US & European markets. We believe exports to remain subdued and lead to lower profitability in near term.

China+1? Brace for China 2.0!

Quick Pointers

- Our channel checks suggest that demand continues to remain sluggish
- Contrary to expectations, Chinese companies continue to build large chemical capacities

In 2017, ~40% of Chinese chemical companies were shut due to environmental concerns. China+1 had become a buzzword and Indian companies were expected to rise to the occasion with what appeared a perennial window for expansion and growth. EBITDA of our coverage universe registered ~24% CAGR during FY16-23. However, concerns on global economic recovery post COVID and inventory stocking amidst a weak demand resulted in EBITDA declining 18% YoY in H1FY24 and EBITDAM declining 250bps YoY. Although most listed Indian companies talk about completion of inventory destocking and normalization of demand, our channel checks suggest that we are almost a year away. Further, our research shows that the dragon is amassing capacities across chemicals, resulting in what one may call China 2.0 instead of China+1!

Decline amidst inventory stocking in H1FY24: Our coverage universe of specialty chemical companies (Aarti Industries Ltd, Vinati Organics Ltd, Deepak Nitrite Ltd, NOCIL Ltd, NFIL International Ltd, Jubilant Ingrevia Ltd, Laxmi Organics Ltd, Clean Science Technology Ltd, Fine Organics Ltd, SRF Ltd and Gujarat Fluorochemicals Ltd) registered 18% decline in EBITDA YoY in H1FY24. This was followed with 250bps decline in EBITDAM. Most stark were Gujarat Fluorochemicals Ltd and Nocil Ltd registering sharpest decline of 49% and 39% EBITDA in H1FY24. With respect to decline in EBITDAM, Gujarat Fluorochemicals Ltd and Nocil Ltd were the top two registering ~1000bps and ~500bps decline YoY.

Poor demand outlook by global majors: FMC, in Nov'23, highlights 8% EBITDA growth in 2024, most of which appears to be coming from cost measures. SABIC, one of the largest chemicals player globally, also guides towards a weak 2024. Bridgestone, in its commentary a few days' back guides towards a weak 2024-which does not augur well for rubber chemicals. Our channel checks with unlisted players also suggest similar outlook.

China 2.0: While it is a difficult task to tap capacity announcements across all chemicals, we dug all capacity announcements done by China in 2023 in agrochemicals space. Our study suggests that contrary to the popular belief of China+1, the Chinese players continue to add capacities, at times, comparable to total existing global demand.

Large capacity additions seen: In pyroxasulfone, where Indian players like PI Industries, Crop Science, Best Agro are present, China appears to have announced new capacities of 4,000mtpa in 2023 alone. Global demand itself is of 3,500mtpa. Similarly, for L-glufosinate (UPL, Insecticides India and several others), a total of 30,000mtpa of capacity has been announced in 2023. Additionally, 20,000mtpa is

already under construction. Global demand is ~120,000mtpa. Similar story plays out in other chemicals too.

Concerns for Indian players: As a result of capacity additions amidst sluggish demand, we remain concerned on the prospects of Indian chemical companies. While demand is yet to revive, China ramping up its capacities is likely to spell long term trouble for the Indian players. Out of coverage, we remain bullish only on Navin Fluorine International Ltd and Vinati Organics Ltd.

Top Picks:

- Navin Fluorine International Ltd:** Company's topline & bottom-line grew at CAGR of >20% over FY16-FY23, primarily led by robust growth from specialty chemicals and CDMO business segments. Going forward, we remain bullish on the stock led by its strong focus on late entry products with completion of cGMP4 by CY24 coupled with strong growth from segments such as HPP & CDMO.
- The stock trades at 29x P/E & 20x EV/EBITDA on FY26E numbers. We assign P/E of 30x on FY26E EPS of Rs 134 and arrive at TP of Rs 4007. **"Maintain Buy"**.
- Vinati Organics Ltd:** Company's topline & bottom-line grew at CAGR of ~20% over FY16-FY23. We believe for the company with demand recovery from ATBS, IBB & higher contribution from butyl phenol/antioxidants, robust performance to be seen post FY24. We believe long term story seems to be intact especially with expansion in ATBS and downstream products of butyl phenol. **"Maintain Accumulate"**.
- The stock trades at 34x P/E & 25x EV/EBITDA on FY26E numbers. We assign P/E of 40x on FY26E EPS of Rs 50 and arrive at TP of Rs 1997.

Exhibit 1: Vinati Organics Ltd

Valuation Basis	FY26E
Target P/E (x)	40
EPS	50
Target Price (INR)	1,997

Source: Company, PL

Exhibit 2: Navin Fluorine International Ltd

Valuation Basis	FY26E
Target P/E (x)	30
EPS	134
Target Price (INR)	4,007


Source: Company, PL

Exhibit 3: EBITDA (Rs mn) of coverage companies (FY16-H1FY24)

EBITDA (Rs mn)	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	H1FY23	H1FY24
Aarti Industries Ltd.	5,723	6,535	6,991	9,651	9,773	9,816	17,201	10,890	5,485	4,360
Clean Science and Technology Ltd.	478	723	729	1,363	1,853	2,590	2,999	4,021	1,888	1,510
Deepak Nitrite Ltd.	1,668	1,355	1,963	4,139	10,258	12,470	16,036	12,894	6,268	5,120
Fine Organic Industries Ltd.	1,469	1,467	1,640	2,223	2,361	1,921	3,485	7,813	4,194	2,562
Gujarat Fluorochemicals Ltd.	13,093	11,745	7,535	8,171	4,716	6,376	11,976	19,653	9,947	5,110
Laxmi Organic Industries Ltd.	768	1,169	1,514	1,533	1,135	2,167	3,676	2,445	1,290	1,163
Navin Fluorine International Ltd.	1,161	1,499	2,107	2,181	2,607	3,108	3,548	5,503	1,930	2,126
NOCIL Ltd.	1,394	1,592	2,654	2,927	1,782	1,308	2,862	2,528	1,653	1,008
SRF Ltd.	9,625	9,969	9,526	12,970	14,549	21,452	31,759	35,292	17,641	13,225
Jubilant Ingrevia Ltd.	-	-	-	-	-	1,171	8,318	5,471	2,938	2,343
Vinati Organics Ltd.	2,068	2,170	1,973	4,234	4,139	3,525	4,341	5,954	2,793	2,198

Source: Company, PL

Exhibit 4: Poor commentaries for 2024 by global majors



Source: Company, PL


Exhibit 5: List of capacity additions announced in China in 2023

Date	Company	Product	Capacity (mtpa)	Capex (RMBmn)	Start by	Indian peers in particular product
13-Dec-23	Zhanhua Guochang Fine Chemical	pyroxasulfone	2,000			PI Industries, Crop Science, Best Agro
13-Dec-23	Haili Guixi New Material Technology	pirimiphos-methyl	3,000	173	2023	None
12-Dec-23	Rainbow Agro	pyroxasulfone	2,000	300		PI Industries, Crop Science, Best Agro
08-Dec-23	Zhongshan Chemical	propanil	7,000		2023	UPL, Best Crop Sc, Meghmani, Ichiban, Insecticides India
27-Nov-23	Yonon	L-glufosinate, picloram, diquat, spirodiclofen	10,000 / 6,800 / 15,000 / 2,000	800		UPL, Best Crop Sc, Insecticides India, Ichiban, Crop Life, Hetban, Bharat Rasayan, Canary Agro, Peptech, NACL, Coromandel, Agrow
27-Nov-23	Rainbow Agro	clethodim, 2,4-D & 2,4-D isooctyl ester, clopyralid, flumioxazin	8,000 / 60,000 / 1,000 / 1,000	2,680		2,4-D (Atul, Artee Minerals, Dhanuka, Meghmani, Heranba)
02-Nov-23	Shandong United Pesticide Industry	cyflumetofen	700	582		
31-Oct-23	Hubei Xingchen Technology	2,4-D	50,000			Atul, Artee Minerals, Dhanuka, Meghmani, Heranba
26-Oct-23	UPL Jiangsu	pesticide formulation	50,000	USD50mn		
19-Oct-23	Lanzhou Xinlongtai Biotechnology	glyphosate	30,000	120		Atul & several others
17-Oct-23	Xinji Alpha Biotechnology	bentazone	5,500	100	2023	
22-Sep-23	Inner Mongolia Yongtai Chemical Co	difluorobenzene, prothioconazole, chlorantraniliprole	200 / 500 / 500	20	2025	chlorantraniliprole (Natco, Best Crop, Insecticides India & others)
20-Sep-23	Hubei Shengkang Chemical Co	chlorantraniliprole intermediates	25,458	500	2025/26	
20-Sep-23	Anhui Red Sun	L-glufosinate	10,000	108		UPL, Best Crop Sc, Insecticides India, Ichiban, Crop Life, Hetban, Bharat Rasayan, Canary Agro, Peptech, NACL, Coromandel, Agrow
05-Sep-23	Limin Co	tembotrione intermediate	600	60		Insecticide India, Best Crop
05-Sep-23	Liaoning Youchuang	cyhalothrin, tetrachlorantraniliprole, imazethapyr and anilofos, SYP-Z048 and pydiflumetofen	15,650			cyhalothrin (Sumitomo, Crystal Crop, imazethapyr (several)
23-Aug-23	Qingdao Hengning Biotechnology Co	5-methyl-2-nitrobenzoic acid and annual 263.1-ton 3-Methyl-4-nitrobenzoic acid (by-product), 20,000-ton Bis(trichloromethyl)carbonate, 3,000-ton trifloxystrobin, 4,000-ton 2,3 dichloropyridine, 3,000-ton 3-Methyl-2-nitrobenzoic acid (technical material), 2500-ton oxime ether, 2,000-ton (trifluoromethyl)acetophenone, 7,500-ton 2,6-dichloropyridine and 7,200-ton 2,3,6-trichloropyridine		685		
21-Aug-23	Hebei Veyong Biochemical	L-glufosinate	10,000	330		UPL, Best Crop Sc, Insecticides India, Ichiban, Crop Life, Hetban, Bharat Rasayan, Canary Agro, Peptech, NACL, Coromandel, Agrow
21-Aug-23	Changqing Agrochemical	s-metoachlor	10,000		2,023	Best Crop, Ichiban, Agro Life
11-Aug-23	Nanjing Red Sun	chlorantraniliprole	2,000		2,023	chlorantraniliprole (Natco, Best Crop,

11-Aug-23	Hebei Lansheng Biotechnology Co	clethodim, boscalid	25,005	25		Insecticides India & others boscalid (UPL, Coromandel)
10-Aug-23	Anhui Ningyitai Technology Co	topramezone	500			BASF, SRF
03-Aug-23	Shandong Huayang Pesticide Chemical Group	acephate	5,000	307		Heranba, UPL, Meghmani, Sudarshan & several others
03-Aug-23	Hubei Taisheng Chemical Co	L-glufosinate ammonium	50,000	5,000		UPL, Best Agro, Coromandel & others
10-Jul-23	Zhejiang Udragon Bioscience Co	600 t/a of prothioconazole, 50 t/a of ipconazole, 200 t/a of metconazole, 200 t/a of cyproconazole, 200 t/a of tiorantraniliprole, 200 t/a of zoxamide, 50 t/a of famoxadone, 50 t/a of spirotbudifen, 200 t/a of MPPZ, 50 t/a of benziothiazolinone, and 250 t/a of fludioxonil		450		
03-Jul-23	Hebang	PMIDA	5,00,000	4,600		
12-May-23	Jingzhou Sancaitang Chemical Technology Co	thiabendazole	2,000	200		
28-Apr-23	Cynda	clethodim	5,000	66		
17-Apr-23	Liaoning Youchuang Crop Protection Co	imazethapyr, pyrisoxazole, cyhalothrin, pydiflumetofen, anilofos and tetrachlorantraniliprole	22,650	4,238	2025/26	imazethapyr (Astec, UPL & several others), cyhalothrin (Rallis, Nagarjuna, Atul, UPL & others), anilofos (Bayer, Gharda, Hyd Chemicals)
17-Mar-23	Gansu Beida Biotechnology Co	difenoconazole, prothioconazole, zoxamide, tiorantraniliprole, flufenacet and fludioxonil	22,000			difenoconazole (Astec & others)
11-Jan-23	Gansu Yinglong Biotechnology Co	800-ton amicarbazone, 150-ton penoxsulam and 1,000-ton dinotefuran				penoxsulam (Meghmani, Deccan, Coromandel & several others), dinotefuran (Insecticides India, Heranba & others)
04-Jan-23	Cynda	200-ton imazapic, 1,200-ton imazethapyr and 100-ton imazaquin technicals, 2,000-ton butyronitrile and 1,500-ton butyrylamide intermediates				Astec, UPL & several others

Source: agropages.com, PL

Exhibit 6: Capacity announced vs global demand for few products



Source: Industry, PL

Exhibit 7: EBITDA Margins of Coverage Universe (FY16-H1FY24)

EBITDA Margins (%)	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	H1FY23	H1FY24
Aarti Industries Ltd.	19.0	20.7	18.4	23.2	23.3	21.8	28.3	16.5	16.6	15.2
Clean Science and Technology Ltd.	33.0	37.9	30.3	34.7	44.2	50.5	43.8	43.0	40.9	39.2
Deepak Nitrite Ltd.	11.4	9.3	11.7	15.3	24.3	28.6	23.6	16.2	15.7	14.9
Fine Organic Industries Ltd.	21.2	18.0	19.0	21.3	23.0	17.1	18.8	25.8	26.5	25.5
Gujarat Fluorochemicals Ltd.	18.7	18.7	19.4	29.9	18.1	24.1	30.3	34.6	35.6	23.7
Laxmi Organic Industries Ltd.	7.3	10.9	11.0	9.8	7.4	12.3	11.9	8.7	9.2	8.4
Navin Fluorine International Ltd.	17.1	20.3	23.8	22.8	25.5	27.4	24.4	26.5	24.0	22.0
NOCIL Ltd.	19.5	21.5	27.4	28.1	21.1	14.1	18.2	15.6	18.4	13.5
SRF Ltd.	21.0	20.7	17.0	18.3	20.2	25.5	25.5	23.7	23.1	20.3
Jubilant Ingrevia Ltd.	-	-	-	-	-	17.1	16.8	11.5	11.2	11.9
Vinati Organics Ltd.	32.8	31.8	26.6	37.5	40.2	36.9	26.9	28.6	26.0	25.0

Source: Company, PL

Exhibit 8: Valuation table

	Revenue Rs mn			EBITDA Rs mn			ROE (%)			PE (x)			EV/EBITDA (x)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
ARTO IN	70,008	76,819	84,072	11,941	14,220	16,191	11.0	12.0	12.5	39.3	33.1	29.2	21.4	18.3	16.1
CLEAN IN	8,114	8,878	9,984	3,383	3,684	4,243	21.5	20.2	19.6	67.7	60.6	53.1	47.3	43.3	37.4
DN IN	84,976	94,272	1,04,933	13,615	17,517	19,740	18.8	20.1	19.1	37.3	29.3	26.0	23.2	18.1	16.0
FINEORG IN	24,246	25,458	26,731	5,734	5,544	5,577	25.9	21.3	19.1	32.9	34.1	32.9	23.3	23.6	22.9
FLUOROCH IN	44,211	48,972	62,183	11,872	13,638	18,980	11.0	11.1	14.5	57.3	51.1	34.8	32.0	27.9	20.1
JUBLINGR IN	47,223	54,255	60,506	5,352	6,628	7,233	10.0	11.8	12.0	27.4	21.3	19.0	15.0	12.3	11.3
LXCHEM IN	25,683	31,521	35,765	3,073	4,095	4,820	10.3	13.3	14.9	49.7	34.8	27.3	25.3	18.7	15.4
NFIL IN	24,303	31,152	36,218	6,282	8,325	9,790	16.8	20.2	20.3	48.3	34.4	28.9	31.9	24.1	20.4
NOCIL IN	14,986	17,308	19,905	2,218	2,605	3,061	7.8	9.3	10.4	36.7	29.3	24.2	19.0	15.7	13.0
SRF IN	1,39,847	1,61,298	1,79,041	30,983	36,024	41,694	15.1	15.3	15.6	43.1	37.1	31.9	24.5	21.1	18.2
VO IN	19,881	23,435	26,788	5,290	6,021	6,862	16.6	16.3	16.3	44.5	39.4	34.4	33.1	28.8	24.9

Source: Company, PL

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	Accumulate	584	510
2	Bayer Cropscience	Accumulate	5,920	5,193
3	Bharat Petroleum Corporation	Reduce	365	429
4	Bharti Airtel	Accumulate	993	924
5	Clean Science and Technology	Hold	1,368	1,374
6	Deepak Nitrite	Reduce	1,935	2,076
7	Dhanuka Agritech	BUY	1,060	883
8	Fine Organic Industries	Hold	4,252	4,250
9	GAIL (India)	BUY	151	124
10	Godrej Agrovet	Hold	420	515
11	Gujarat Fluorochemicals	Reduce	2,413	2,780
12	Gujarat Gas	Accumulate	477	419
13	Gujarat State Petronet	BUY	328	273
14	Hindustan Petroleum Corporation	Sell	272	342
15	Indian Oil Corporation	Reduce	94	109
16	Indraprastha Gas	Hold	406	390
17	Insecticides India	Accumulate	600	519
18	Jubilant Ingrevia	Hold	433	412
19	Laxmi Organic Industries	Reduce	220	254
20	Mahanagar Gas	Hold	1,065	1,015
21	Mangalore Refinery & Petrochemicals	Hold	94	96
22	Navin Fluorine International	BUY	4,007	3,430
23	NOCIL	Reduce	226	246
24	Oil & Natural Gas Corporation	BUY	237	196
25	Oil India	BUY	368	302
26	P.I. Industries	BUY	4,600	3,648
27	Petronet LNG	Hold	208	196
28	Rallis India	Reduce	190	217
29	Reliance Industries	Accumulate	2,618	2,388

PL's Recommendation Nomenclature

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I Mr. Swarnendu Bhushan- IIT, MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan- IIT, MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com